Omnivox Adverse Reactions

Serious adverse events may occur with therapeutic use or with acute overdose. At therapeutic doses adverse events may include: Irreversible peripheral neuropathy, central nervous system toxicity, cardiovascular toxicity, tendon/articular toxicity, and hepatic toxicity. Toxic epidermal necrolysis, coagulation abnormalities and pancytopenia are other possible adverse effect of levofloxacin. Children and the elderly are believed to be at a greater risk. Adverse reactions may manifest during, as well as after fluoroquinolone therapy. Liver damage and dysglycemia has been associated with levofloxacin. Another serious adverse effect is autoimmune hemolytic anemia. Older patients may have an increased risk of tendinopathy (including rupture), especially with concomitant corticosteroid use and such patients may also be more susceptible to prolongation of the QT interval. Patients with known prolongation, those with hypokalemia, or being treated with other drugs that prolong the QT interval should avoid the use of levaquin. Hematologic reactions (including agranulocytosis, thrombocytopenia), and renal toxicities may occur after multiple doses.
Post-Marketing Adverse Reaction: Additional adverse events reported from worldwide post-marketing experience with levofloxacin include: allergic pneumonitis, anaphylactic shock, anaphylactoid reaction, dysphonia, abnormal EEG, encephalopathy, eosinophilia, erythema multiforme, hemolytic anemia, multi-system organ failure, increased International Normalized Ratio (INR)/prothrombin time, peripheral neuropathy, rhabdomyolysis, Stevens-Johnson Syndrome, tendon rupture, torsades de pointes, vasodilation.